Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review [PDF]
Journal of Ophthalmology, 2021 Corticosteroids are used in a variety of ophthalmological diseases. One challenge faced by ophthalmologists is to deliver corticosteroids to the posterior segment of the eye with efficacy and safety.
Flávio Ribeiro, Manuel S. Falcão
doaj +6 more sources
Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant [PDF]
Pharmaceutics, 2022 To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (
Stephanie Baillif +2 more
exaly +7 more sources
Case Reports in Ophthalmological Medicine, 2022 Purpose. To describe an alternative treatment for a patient with serpiginous choroiditis (SC) who was not tolerant to systemic therapies. Methods. Case report of a patient with serpiginous choroiditis with their clinical course followed with ophthalmic ...
Yousuf Siddiqui +4 more
doaj +5 more sources
CHOROIDAL LESIONS UNRESPONSIVE TO FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN BIRDSHOT CHORIORETINOPATHY. [PDF]
Retin Cases Brief Rep, 2022 Purpose: To report the persistence of choroidal lesions despite fluocinolone acetonide intravitreal implants and their resolution with oral prednisone treatment. Methods: Retrospective chart review of a birdshot chorioretinopathy patient at a tertiary referral clinic.
Cheng SK +3 more
europepmc +3 more sources
Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®) [PDF]
Journal of Ophthalmic Inflammation and Infection, 2020 Background The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious ...
Bahram Bodaghi +4 more
doaj +2 more sources
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience [PDF]
Scientific Reports, 2021 We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME ...
Matteo Fallico +14 more
doaj +2 more sources
Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis [PDF]
International Medical Case Reports Journal, 2022 Adrian T Babel,1,2 Eric K Chin,3,4 David RP Almeida2 1Boonshoft School of Medicine, Dayton, OH, USA; 2Erie Retinal Surgery, Erie, PA, USA; 3Retina Consultants of Southern California, Redlands, CA, USA; 4Loma Linda Eye Institute, Veterans Affair Hospital,
Babel AT, Chin EK, Almeida DRP
doaj +2 more sources
Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren’s syndrome-related keratopathy: a case report [PDF]
Journal of Medical Case Reports, 2019 Background In this report, we present the results of a severe case of Sjögren’s syndrome-related keratopathy after fluocinolone acetonide 190-μg intravitreal implant (Iluvien®; Alimera Sciences Inc.) therapy.
Joanna Wasielica-Poslednik +2 more
doaj +2 more sources
Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis [PDF]
Journal of Clinical Medicine, 2021 The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months. Macular edema was resolved in 24 (70.6%) cases.
Gerd U Auffarth,, Febo +2 more
exaly +3 more sources
The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. [PDF]
Eye (Lond), 2021 To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO).Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX ...
Cicinelli MV +9 more
europepmc +6 more sources